Background: Nomograms are visual predictive tools that are widely used for estimating cancer prognosis. The purpose of this study was to develop a prognostic tool that will accurately predict overall survival (OS) in individual patients with oral cancer.
Methods: Medical records of 609 patients with cancer of the oral cavity were retrospectively analyzed. The stepdown method was used to select the statistically most influential predictors for inclusion in the final nomogram for predicting OS.
Results: The most influential predictors of mortality probability were age, comorbidities, clinical lymph node status, stage of disease, tumor thickness, differentiation, and perineural invasion. Nomogram was developed for prediction of 5-year OS.
Conclusion: Nomogram has been widely used in a number of cancers, but its application in oral cancer prognostication has not been explored. In this study, we have developed a nomogram that can accurately estimate 5-year OS in patients with oral cavity cancer. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1826-1831, 2016.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/hed.24507 | DOI Listing |
BDJ Open
December 2024
School of Public Health, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia.
Background: Mefakia is a well-known traditional chewing wood used in Ethiopia to cleanse the mouth. Although mefakia is used in parallel with modern toothbrushes to improve oral hygiene, there is a gap in the literature regarding its comparative performance in removing plaque and maintaining good oral hygiene.
Objective: This study aimed to evaluate and compare the oral hygiene status of patients using mefakia and modern toothbrushes at the Holy Bethel Dental Clinic in Addis Ababa, Ethiopia.
BMC Anesthesiol
December 2024
Department of Anesthesiology, The First People's Hospital of Foshan, Lingnan Road 81#, Foshan City, 528000, China.
Background: There is controversy surrounding the influence of dexmedetomidine on the recovery of postoperative gastrointestinal dysfunction in patients under general anesthesia. The main purpose of this meta-analysis is to evaluate the effect of dexmedetomidine administration during the perioperative period on the recovery of gastrointestinal function in patients under general anesthesia.
Methods: A systematic review and meta-analysis with trial sequential analysis was performed to identify randomized controlled trials comparing dexmedetomidine administration with placebo for the recovery of gastrointestinal function.
Oral Maxillofac Surg Clin North Am
December 2024
Private Practice, Brooklyn, NY, USA.
Complete arch oral implant treatment using photogrammetry was studied in 77 patients with 111 arches focusing on digitization of clinical records and optimization of the provisional. The aim of the study was to test the hypothesis that patient satisfaction with the provisional prosthesis during the first 4 months of care determined workflow efficiency and success. Digitization of 8 clinical records was done including centric relation, vertical dimension, esthetics, occlusion, inter-arch space, abutment selection, abutment capture, and soft tissue scan.
View Article and Find Full Text PDFOral Surg Oral Med Oral Pathol Oral Radiol
October 2024
Department of Biomedical Engineering, Ankara University, Ankara, Turkey.
Objective: The production of 3-dimensional models and materials according to preoperative virtual surgical planning is a time-consuming process and causes high costs. We aimed to demonstrate the navigation mediated reconstruction of the patients who underwent the removal of a tumoral mass in midfacial region according to their preoperatively prepared surgical plannings.
Study Design: Patients who underwent the removal of tumoral mass and reconstruction in their midfacial region were included in the study.
Clin Lymphoma Myeloma Leuk
December 2024
Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY.
In the past decade, the treatment paradigm for chronic lymphocytic leukemia (CLL) has markedly shifted from traditional chemoimmunotherapy towards targeted therapies. A fixed-duration, targeted regimen with venetoclax, a potent oral BCL-2 inhibitor, combined with obinutuzumab, a glycoengineered type II anti-CD20 monoclonal antibody (Ven-Obi), has become the standard to beat for time-limited therapy in CLL. Ven-Obi allows for the rapid induction of remissions with high rates of undetectable minimal residual disease (uMRD) in patients across different treatment settings.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!